Table 3.
Statistical Comparison of Clinical Data between AML Patients with SALL4 Gene Expression ≤ 1.0 RQ and Patients >1.0 RQ
|
SALL4 ≤ 1.0 RQ (No=22) |
SALL4 >1.0 RQ (No=30) |
Significance P-value |
|
|---|---|---|---|
| Age (y) | Median:43.5 Range:22-65 Mean±SD: 42±65 |
Median:42 Range:19-70 Mean±SD: 39.7±14 |
0.49 |
| Sex | |||
| Female (No= 34) | 13 (38.2%) | 21 (61.8%) | 0.41 |
| Male (No =18) | 9 (50.0%) | 9(50.0%) | |
| Hepatomegaly (No= 26) |
14 (53.8%) | 12 (46.2%) | 0.09 |
| Splenomegaly (No= 23) |
13 (56.5%) | 10 (43.5%) | 0.07 |
| Lymphadenopathy (No= 19) |
10 (52.6%) | 9 (47.4%) | 0.25 |
| WBCs(x109/l) | 43±62.7 | 53.9±102.4 | 0.52 |
| Hb (g/dl) | 7.4± 1.4 | 8.2 ±2.2 | 0.31 |
| Platelet (x109/l) | 45.6±36.5 | 101.7±181.4 | 0.47 |
| Peripheral blood blast % | 52.3±28.7 | 41.6±25.7 | 0.14 |
| BM blasts% at presentation | 62.9±22.3 | 58.7±24.0 | 0.59 |
P ≤ 0.05 is considered significant